Comparison

GLP-1 coverage by state

Only 13 state Medicaid programmes cover GLP-1s for obesity. Four dropped coverage in the last year. Here is the national picture and where it changed.

Simplified illustrated map of the United States

Updated 2026-09-18


Coverage of GLP-1s for obesity is optional for state Medicaid programmes. Thirteen states exercise that option; the rest do not.

Coverage of GLP-1s for obesity is optional for state Medicaid programmes. As of January 2026, 13 covered them under fee-for-service — down from 16 in October 2025. Source: KFF, “Medicaid Coverage of and Spending on GLP-1s”, 16 January 2026.

States where coverage has been proposed for removal

Massachusetts and Rhode Island both had live proposals to end Medicaid coverage of GLP-1s for weight loss as of April 2026. Neither had taken effect at the time of reporting. If you are eligible in either state, the sensible read is that the window may not stay open.

States that eliminated coverage

California, Pennsylvania, South Carolina, New Hampshire all ended coverage of GLP-1s for obesity after October 2025, which KFF attributes to budget pressure and drug cost.

States that changed course

North Carolina dropped coverage in October 2025 during a budget stalemate and reinstated it that December — the change that brought the national total back to 13.

Time-limited coverage

Utah reported that funding for coverage was limited to fiscal year 2026 — a deadline rather than a refusal.

The states at the extremes

West Virginia, Mississippi, Colorado stand out on prevalence rather than policy. Every US state and territory recorded adult obesity prevalence of at least 25% in 2024.

RegionAdult obesity prevalence, 2024
Midwest35.9%
South34.5%
Northeast30.3%
West30.2%

Among adults aged 40-59 — the age band most of our readers fall into — 43 states and 3 territories recorded prevalence of 35% or higher. Source: CDC Adult Obesity Prevalence Maps, 2024 data, published 3 December 2025.

If your state is not listed above

Then we have nothing state-specific and verifiable to tell you, and we would rather say so than pad this out. Every provider we track is 50-state telehealth charging the same price wherever you live, so there is no local market to report. What to do instead: ring your plan and ask about the specific medication by name.

Important. True in every state. Coverage for obesity is optional, but coverage is required for type 2 diabetes, cardiovascular disease (Wegovy, since March 2024) and moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound, since December 2024). A refusal for weight loss is not a refusal under those indications.

Paying cash, wherever you are

Dispensed byProductPer monthScore
Coreage Rx
Best overall on true monthly cost
Compounded$1994.5
SuperHealthy Rx
Public offer; not independently scored
Compounded$135Not scored
Likeness Rx
Public offer; not independently scored
Compounded$199Not scored
Trimi
Lowest flat price with named pharmacies
Compounded$1254.6
PlexusDx
Pharmacy transparency and genetic testing
Compounded$1894.4
Ozari Health
Lowest advertised semaglutide price
Compounded$1254.4
Fifty 410
Prepaid blocks with no subscription
Compounded$1334.2
Ivím Health
Unlimited clinician access
Compounded$1994

Read next

  • Medicare, GLP-1s and the $50 month

    CMS is running a time-limited programme giving eligible Part D members certain GLP-1s for $50 a month. If you are on Medicare, read this before paying cash for anything.

  • Providers that work your insurance

    Prior authorisations, appeals and coverage checks. For anyone whose plan might say yes, this is worth more than any discount.

  • GLP-1 coverage in California

    Medicaid no longer covers GLP-1s for obesity here. What that means, the indications that are still mandatory, and what it costs if you pay cash.

  • GLP-1 coverage in Texas

    Medicaid covers weight-loss drugs but no GLP-1s. What that means, the indications that are still mandatory, and what it costs if you pay cash.

Coreage Rx pays us a commission on sign-ups through our links. It does not affect our scores or rankings. How we rate · Disclosure